FGFR4 Amplification

CI-VAR-00000245Explore in graph →CIViC 2907

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Ewing Sarcoma1
FGFR4 Amplification	Pazopanib	Predictive	C	Supports Sensitivity Response	2	submitted	EID7836 Clinical trial of soft tissue sarcoma patients found no responses to pazopanib + trametinib combination in Ewing sarcoma patients. Comparison was done to previously treated Ewing sarcoma that responde… (full text at CIViC) PMID 28377484 · Subbiah et al., 2017 · Open in CIViC	civic
Malignant Neoplasm1
FGFR1 Amplification OR FGFR2 Amplification OR FGFR3 Amplification OR FGFR4 Amplification	Erdafitinib	Predictive	B	Does Not Support Sensitivity Response	3	submitted	EID12024 In this phase II trial, 35 patients harbouring tumours with FGFR1-4 amplifications were treated with FGFR1-4 inhibitor, erdafitinib. 33 of the 35 patients were eligible and treated, while biopsies wer… (full text at CIViC)

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.